Propanc Biopharma, Inc. Logo

Propanc Biopharma, Inc.

Developing proenzyme therapies to prevent solid tumor recurrence and metastasis.

PPCB | NDAQ

Overview

Corporate Details

ISIN(s):
US74346N4043
LEI:
Country:
United States of America
Address:
302/6 BUTLER STREET, 3124 CAMBERWELL, VICTORIA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Propanc Biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in the research and development of novel cancer treatments. The company focuses on preventing the recurrence and metastasis of solid tumors, particularly for patients with pancreatic, ovarian, and colorectal cancers. Its lead product candidate, PRP, is a pancreatic proenzyme formulation designed to suppress tumor cell migration, inhibit blood vessel formation within tumors, and induce cancer cell death. Propanc's goal is to develop an effective and well-tolerated therapy suitable for long-term, chronic use in cancer management.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Propanc Biopharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Propanc Biopharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Propanc Biopharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Alpha Cognition Inc. Logo
Develops and commercializes novel treatments for neurodegenerative diseases like Alzheimer's and ALS.
United States of America ACOG
Alteogen Inc. Logo
Biotech firm developing next-gen ADCs and biobetters with proprietary platform technologies.
South Korea 196170
ALTERITY THERAPEUTICS LTD Logo
Developing therapies for Parkinsonian disorders and MSA by inhibiting protein aggregation.
United States of America ATHE
Alto Neuroscience, Inc. Logo
Developing precision medicines for depression and schizophrenia using a brain biomarker platform.
United States of America ANRO
ALUMIS INC. Logo
Develops targeted oral therapies for immune-mediated diseases using precision immunology.
United States of America ALMS
Alvotech Logo
Develops and manufactures affordable biosimilar medicines for patients worldwide.
United States of America ALVO
Alvotech Holdings S.A Logo
Develops and manufactures affordable biosimilar medicines for global patient access.
Luxembourg ALVO
ALX ONCOLOGY HOLDINGS INC Logo
Clinical-stage firm developing CD47 inhibitors for hematologic and solid tumors.
United States of America ALXO
Alzamend Neuro, Inc. Logo
Developing lithium & vaccine therapies for neurodegenerative & psychiatric disorders.
United States of America ALZN
Alzinova AB Logo
Developing targeted immunotherapies, including a vaccine, for Alzheimer's disease.
Sweden ALZ

Talk to a Data Expert

Have a question? We'll get back to you promptly.